Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2010 - 2026)

Nektar Therapeutics' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 25.01% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 25.01% increase from a year earlier, with the FY2025 full-year figure at $8.6 million, up 19.11% from the prior year.
• Other Non-Current Liabilities fell to $8.4 million in Q1 2026 per NKTR's latest filing, from $8.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $8.6 million in Q4 2025 and bottomed at $2.1 million in Q2 2022.
• The 5-year median for Other Non-Current Liabilities is $6.5 million (2023), against an average of $6.1 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 48.21% in 2022 and jumped 147.64% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $7.6 million in 2022, then plunged by 38.62% to $4.6 million in 2023, then jumped by 56.22% to $7.2 million in 2024, then climbed by 19.11% to $8.6 million in 2025, then fell by 2.08% to $8.4 million in 2026.
• Per Business Quant, the three latest NKTR Other Non-Current Liabilities figures stand at $8.4 million (Q1 2026), $8.6 million (Q4 2025), and $5.0 million (Q3 2025).